Skip to main content
. 2025 Jul 10;23:330. doi: 10.1186/s12964-025-02245-5

Table 1.

Relationship between the IgSF11 signal and clinicopathological factors in patients with melanoma (n = 187)

Parameter Total Low IgSF11 High IgSF11 p-value
(n = 130) (n = 57)
Age 0.890
 < 70 90 (48.1) 63 (48.4) 27 (44.8)
 ≥ 70 97 (51.8) 67 (51.5) 30 (55.2)
Gender 0.288
Male 94 (50.2) 62 (47.6) 32 (56.1)
Female 93 (49.7) 68 (52.3) 25 (43.8)
Tumor size (cm) 0.565
 < 10 12 (6.4) 7 (5.3) 5 (8.7)
 < 20 84 (44.9) 59 (45.3) 25 (43.8)
 < 30 28 (14.9) 18 (13.8) 10 (17.5)
 < 40 32 (17.1) 26 (20.0) 6 (10.5)
 ≥ 40 22 (11.7) 13 (10.0) 9 (15.7)
Unknown 9 (4.8) 7 (5.3) 2 (3.5)
Clark’s level  < 0.001
I 33 (17.6) 33 (25.3) 0 (0.0)
II 28 (14.9) 24 (18.4) 4 (7.0)
III 30 (16.0) 16 (12.3) 14 (24.5)
IV 51 (27.2) 29 (22.3) 22 (38.5)
V 37 (19.7) 25 (19.2) 12 (21.0)
Unknown 8 (4.2) 3 (2.3) 5 (8.7)
Budding 0.020
 < 5 33 (17.6) 25 (19.2) 8 (14.0)
 ≥ 5 75 (25.1) 39 (30.0) 36 (63.1)
Unknown 18 (9.6) 9 (6.9) 9 (15.7)
Clark’s level I/II 61 (32.6) 57 (43.8) 4 (7.01)
Spindle cells 0.095
(–) 157 (83.9) 113 (86.9) 44 (77.1)
(+) 30 (16.0) 17 (13.0) 13 (22.8)
Lymph node metastasis 0.088
(–) 128 (68.4) 93 (71.5) 35 (61.4)
(+) 41 (21.9) 24 (18.4) 17 (29.8)
Unknown 18 (9.6) 13 (10.0) 5 (8.7)
Distant metastasis 0.137
(–) 164 (87.7) 114 (87.6) 50 (87.7)
(+) 7 (3.7) 3 (2.3) 4 (7.0)
Unknown 16 (8.5) 13 (10.0) 3 (5.2)
TNM stage 0.030
0/I/II 123 (65.7) 91 (70.0) 32 (56.1)
III/IV 49 (26.2) 28 (21.5) 21 (36.8)
Unknown 15 (8.0) 11 (8.4) 4 (7.0)
BRAFV600E gene mutation 0.642
(–) 23 (12.2) 16 (12.3) 7 (12.2)
(+) 9 (4.8) 7 (5.3) 2 (3.5)
Unknown 155 (82.8) 107 (82.3) 48 (84.2)
Recurrence 0.082
(–) 119 (63.6) 88 (67.6) 31 (54.3)
(+) 68 (36.3) 42 (32.3) 26 (45.6)